| P2093 | author name string | Amrita Krishnan | |
| | Gösta Gahrton | |
| P2860 | cites work | Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning | Q44418467 |
| | Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. | Q44616173 |
| | Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability | Q44835439 |
| | Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation | Q44888557 |
| | Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. | Q45005783 |
| | Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). | Q45143154 |
| | Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma | Q45260013 |
| | Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. | Q45361447 |
| | Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. | Q45987373 |
| | Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group | Q46508141 |
| | Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. | Q51395943 |
| | Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. | Q54774369 |
| | Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma | Q57209660 |
| | Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres | Q57904065 |
| | Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy | Q58415992 |
| | Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants | Q29619458 |
| | Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting | Q30486842 |
| | Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project | Q30571858 |
| | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 |
| | High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma | Q33378693 |
| | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial | Q33387733 |
| | Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy | Q33969561 |
| | Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib | Q34332019 |
| | A comparison of allografting with autografting for newly diagnosed myeloma | Q34577703 |
| | Bone-marrow transplantation (first of two parts). | Q34649003 |
| | Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 |
| | Clinical developments in reduced intensity haematopoietic stem cell transplantation | Q34974730 |
| | Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias | Q35462258 |
| | Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma | Q35651684 |
| | Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma | Q36148528 |
| | Highly activated and expanded natural killer cells for multiple myeloma immunotherapy | Q36216203 |
| | Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy. | Q36366589 |
| | Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial | Q36725446 |
| | Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation | Q36797759 |
| | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy | Q36805875 |
| | A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97 | Q37088191 |
| | International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma | Q37778947 |
| | Clinical impact of chromosomal aberrations in multiple myeloma | Q37821077 |
| | Drug safety evaluation of defibrotide | Q38066257 |
| | Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation | Q38086718 |
| | Bone-marrow transplantation (second of two parts). | Q38091044 |
| | Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. | Q39679501 |
| | Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation | Q39959239 |
| | Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation | Q43242678 |
| | Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). | Q43250016 |
| | Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. | Q43640246 |
| | Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation | Q43707069 |
| | Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up | Q44021179 |
| | The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants | Q44104454 |
| | End-of-life care discussions in patients with advanced cancer | Q44151813 |
| P433 | issue | 1 | |
| P304 | page(s) | 79-90 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Expert Review of Hematology | Q15734429 |
| P1476 | title | Allogeneic transplantation in multiple myeloma. | |
| P478 | volume | 7 | |